Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2C
The experimentally established mechanism targets of Xylometazoline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 7/20 | 0.97 |
| ▸ | ADRA2B known ✓ | P18089 | 6/20 | 0.97 |
| ▸ | ADRA2C known ✓ | P18825 | 6/20 | 0.97 |
| ▸ | ADRA1D known ✓ | P25100 | 5/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 5/20 | 0.97 |
| ▸ | ADRA1B known ✓ | P35368 | 5/20 | 0.97 |
| ▸ | HTR1D | P28221 | 12/20 | 0.97 |
| ▸ | HTR1B | P28222 | 10/20 | 0.97 |
| ▸ | HTR1A | P08908 | 4/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.97 |
| ▸ | HTR2A | P28223 | 2/20 | 0.97 |
| ▸ | HTR2C | P28335 | 2/20 | 0.97 |
| ▸ | DRD3 | P35462 | 2/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | DRD2 | P14416 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xylometazoline SCHEMBL34087 | 0.98 | HTR1D (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL3300993 | 0.97 | HTR1D (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL41837 | 0.97 | HTR1A (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL3297417 | 0.97 | HTR1D (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL3299510 | 0.97 | HTR1D (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL6436975 | 0.95 | HTR1A (0.97) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL3300203 | 0.90 | HTR1D (0.84) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL3304354 | 0.90 | HTR1D (0.84) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| Xylometazoline SCHEMBL3301402 | 0.90 | HTR1D (0.84) | HTR1DHTR1BADRA2AADRA2BADRA2C | |
| SCHEMBL8149986 | 0.89 | HTR1D (1.00) | HTR1DHTR1BADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107249566-A | A kind of nasal composition that stability is improved using seawater as excipient | 加德兰-盖林斯基实验室有限责任公司 | 2017-10-13 | — | — | CN | claimed |
| CN-103351343-A | Synthetic method for xylometazoline hydrochloride | TIANJIN HUAJIN PHARMACEUTICAL CO LTD | 2013-10-16 | — | — | CN | claimed |
| US-20220000909-A1 | A NASAL SOLUTION WITH CLOSED BASIN NATURAL SPRING WATER CHARACTERISTIC AND METHOD FOR OBTAINING SAID NASAL SOLUTION | YILDIZ TEKNIK UNIVERSITESI (TR) | 2022-01-06 | — | — | US | disclosed |
| EP-3886812-A1 | A NASAL SOLUTION WITH CLOSED BASIN NATURAL SPRING WATER CHARACTERISTIC AND METHOD FOR OBTAINING SAID NASAL SOLUTION | Yildiz Teknik Universitesi (TR) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020112063-A1 | A NASAL SOLUTION WITH CLOSED BASIN NATURAL SPRING WATER CHARACTERISTIC AND METHOD FOR OBTAINING SAID NASAL SOLUTION | YILDIZ TEKNIK UNIVERSITESI (TR) | 2020-06-04 | — | — | WO | disclosed |
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| CN-107249566-A | A kind of nasal composition that stability is improved using seawater as excipient | 加德兰-盖林斯基实验室有限责任公司 | 2017-10-13 | — | — | CN | disclosed |
| CN-103351343-A | Synthetic method for xylometazoline hydrochloride | TIANJIN HUAJIN PHARMACEUTICAL CO LTD | 2013-10-16 | — | — | CN | disclosed |
| CN-101928247-B | Synthetic method of xylometazoline hydrochloride compound | WUHAN WUYAO TECHNOLOGY CO LTD | 2012-05-09 | — | — | CN | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| CN-101928247-A | Method for synthesizing xylometazoline hydrochloride compound | WUHAN WUYAO TECHNOLOGY CO LTD | 2010-12-29 | — | — | CN | disclosed |
| CN-1290502-C | Compositions for treatment of common cold | NYCOMED DANMARK AS (DK) | 2006-12-20 | — | — | CN | disclosed |
| CN-1555263-A | Compositions for treatment of common cold | ο | 2004-12-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | ADRA2A 331/4885ADRA2B 201/4885ADRA2C 297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.